Key points
- JNJ reached a record peak of $264.98 before rising further to $268.69, posting a daily gain of 3.70%.
- Total returns on an annual basis reach 71%
- Guggenheim raised its price target to $270 with a buy rating, forecasting second-quarter sales of $25.48 billion.
- The company increased its quarterly payout to $1.34 per share from $1.30, extending its dividend growth streak to 55 years.
- Major institutional players, including Vanguard, State Street and Norges Bank, have expanded their stakes significantly
Shares of Johnson & Johnson reached an all-time high on Tuesday, initially touching $264.98 before advancing to $268.69 — representing a 3.70% increase on the day. This valuation puts the healthcare giant’s market value at approximately $646.8 billion.
Over the trailing twelve month period, shares rose a staggering 71%, leaving a twelve month low of $154.21.
At current valuation levels, JNJ is showing a P/E of 31.02 and a PEG ratio of 2.58. The fifty-day moving average is at $233.72, while the two-hundred day moving average is at $231.37 – both well below current trading levels.
Tuesday’s session saw 1.79 million shares traded, significantly lower than the average of 8.41 million. This subdued volume accompanying rising prices often indicates systematic accumulation rather than speculative momentum.
Wall Street goals take effect
Guggenheim recently raised its price target to $270 while reaffirming its buy stance. The investment company expects second-quarter revenues to reach $25.48 billion with earnings per share of $2.87.
Leerink has been promoted JNJ The market underperformed to outperformed in May, resulting in a $265 price target — a threshold the stock has now surpassed. Wells Fargo maintains an overweight position with a target of $263.
The overall view from 27 analysts indicates a “Moderate Buy” recommendation, with an average price target of $257.13. The stock’s current trading level exceeds this consensus, indicating that bullish momentum is exceeding Street expectations.
Both Bank of America and Barclays maintain a neutral/equal weight perspective, with price targets of $254 and $255, respectively.
Financial performance and shareholder returns
The company’s latest quarterly results, revealed on April 14, revealed EPS of $2.70, beating the consensus estimate of $2.68. Total revenue was $24.06 billion versus expectations of $23.60 billion – representing a 9.9% year-over-year expansion.
The company also boosted its quarterly dividend to $1.34 from $1.30, with the payment issued on June 9. This translates to an annual dividend of $5.36, yielding about 2.0% at current prices.
Johnson & Johnson It has now achieved dividend increases for 55 consecutive years, maintaining its prestigious Dividend King status. The current payout ratio is 61.97%.
Fiscal 2026 EPS guidance is between $11.45 and $11.65, with analyst consensus at $11.57.
Institutional accumulation and corporate movements
Institutional ownership represents 69.55% of outstanding shares. Vanguard expanded its position by 3.73 million shares in the fourth quarter, bringing its total to 240.35 million. State Street increased its holdings by 1.66 million to 133.87 million shares. Norges Bank initiated a new stake worth approximately $6.92 billion.
Moran Wealth Management increased its position by 15.4% during the first quarter, acquiring an additional 12,160 units to reach 90,903 shares worth $22.2 million.
In connection with insider transactions, EVP Kathryn Wengel divested 10,000 shares at a price of $241.15 on June 11, reducing her stake by 8.05%. It holds 114,288 shares worth approximately $27.6 million.
The company also unveiled an investment of more than $1 billion in its Jacksonville, Florida, facility to enhance its Vision segment manufacturing capacity, including expanded production of ACUVUE contact lenses.
New clinical data on IMAAVY (nipocalimab-aahu) for the treatment of myasthenia gravis has been shared across 12 research abstracts at the European Academy of Neurology Congress 2026.
